4D Molecular Therapeutics, Inc.

NasdaqGS:FDMT 주식 보고서

시가총액: US$346.7m

4D Molecular Therapeutics 관리

관리 기준 확인 2/4

4D Molecular Therapeutics CEO는 David Kirn, Sep2013 에 임명되었습니다 의 임기는 11.17 년입니다. 총 연간 보상은 $ 10.29M, 5.8% 로 구성됩니다. 5.8% 급여 및 94.2% 보너스(회사 주식 및 옵션 포함). 는 $ 12.44M 가치에 해당하는 회사 주식의 3.59% 직접 소유합니다. 12.44M. 경영진과 이사회의 평균 재임 기간은 각각 3.1 년과 4 년입니다.

주요 정보

David Kirn

최고 경영자

US$10.3m

총 보상

CEO 급여 비율5.8%
CEO 임기11.2yrs
CEO 소유권3.6%
경영진 평균 재임 기간3.1yrs
이사회 평균 재임 기간4yrs

최근 관리 업데이트

Recent updates

Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

Nov 24
Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Oct 04

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

Aug 10
4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

Jul 19

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Apr 29

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Feb 06

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Jan 25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 12
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Nov 08
We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

May 08
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Sep 29
We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

4D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M

Aug 11

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Jun 11
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

CEO 보상 분석

David Kirn 의 보수는 4D Molecular Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$143m

Jun 30 2024n/an/a

-US$110m

Mar 31 2024n/an/a

-US$105m

Dec 31 2023US$10mUS$597k

-US$101m

Sep 30 2023n/an/a

-US$96m

Jun 30 2023n/an/a

-US$111m

Mar 31 2023n/an/a

-US$110m

Dec 31 2022US$3mUS$586k

-US$107m

Sep 30 2022n/an/a

-US$105m

Jun 30 2022n/an/a

-US$102m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$5mUS$570k

-US$71m

Sep 30 2021n/an/a

-US$67m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$702kUS$451k

-US$57m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$61m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$554kUS$430k

-US$49m

Sep 30 2019n/an/a

-US$35m

Jun 30 2019n/an/a

-US$21m

Mar 31 2019n/an/a

-US$15m

Dec 31 2018US$546kUS$396k

-US$10m

보상 대 시장: David 의 총 보상 ($USD 10.29M )은 US 시장( $USD 2.11M ).

보상과 수익: 회사가 수익성이 없는 동안 David 의 보상이 증가했습니다.


CEO

David Kirn (61 yo)

11.2yrs

테뉴어

US$10,286,808

보상

Dr. David H. Kirn, M.D., serves as Director at Coagulant Therapeutics, Inc He co-founded 4D Molecular Therapeutics, Inc. in 2013 and has been its Chief Executive Officer since September 12, 2013. Dr. Kirn...


리더십 팀

이름위치테뉴어보상소유권
John Milligan
Executive Chairman4.3yrsUS$581.44k0.22%
$ 750.0k
David Kirn
Co-Founder11.2yrsUS$10.29m3.59%
$ 12.4m
Fariborz Kamal
President & COO4.8yrsUS$4.54m0.013%
$ 44.6k
Noriyuki Kasahara
Chief Scientific Officerless than a yearUS$488.91k데이터 없음
Robert Kim
Chief Medical Officer2.1yrsUS$3.96m0.0023%
$ 7.8k
Theresa Janke
Co-Founder & Chief of Staff11.8yrsUS$2.70m데이터 없음
Uneek Mehra
Chief Financial & Business Officer1.2yrs데이터 없음데이터 없음
Scott Bizily
Chief Legal Officer & Corporate Secretary3.2yrs데이터 없음0.015%
$ 50.9k
An Song
Chief Development Officer3yrs데이터 없음데이터 없음
Alan Cohen
Senior VP & Therapeutic Area Head of Pulmonologyno data데이터 없음데이터 없음
Christopher Simms
Chief Commercial Officerless than a year데이터 없음데이터 없음
Karen Carothers
Controller8.3yrs데이터 없음데이터 없음

3.1yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: FDMT 의 관리팀은 경험 ( 3.1 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
John Milligan
Executive Chairman4.3yrsUS$581.44k0.22%
$ 750.0k
David Kirn
Co-Founder11.2yrsUS$10.29m3.59%
$ 12.4m
Charles Theuer
Independent Director8.9yrsUS$352.62k0.070%
$ 242.6k
Susannah Gray
Independent Director4.3yrsUS$352.62k0%
$ 0
Paul Utz
Member of Scientific Advisory Boardless than a year데이터 없음데이터 없음
Richard Moss
Member of Scientific Advisory Boardless than a year데이터 없음데이터 없음
Jacob Chacko
Independent Director5.7yrsUS$352.62k0%
$ 0
Shawn Tomasello
Independent Director4yrsUS$345.12k0%
$ 0
Daniel Takefman
Member of Scientific Advisory Boardless than a year데이터 없음데이터 없음
Amit Gaggar
Member of Scientific Advisory Boardless than a year데이터 없음데이터 없음
Nancy Miller-Rich
Independent Director4yrsUS$340.12k0%
$ 0
Arshad Khanani
Chair of Ophthalmology Advisory Boardless than a year데이터 없음데이터 없음

4.0yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: FDMT 의 이사회경험(평균 재직 기간 4 년)으로 간주됩니다.